Jpmorgan Chase & CO Viking Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.51 Trillion
  • Q3 2025

A detailed history of Jpmorgan Chase & CO transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,577,087 shares of VKTX stock, worth $103 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,577,087
Previous 2,577,087 -0.0%
Holding current value
$103 Million
Previous $65.8 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025
SELL
$23.09 - $42.09 $12.7 Million - $23.1 Million
-549,415 Reduced 17.57%
2,577,087 $65.8 Million
Q1 2025

May 12, 2025
BUY
$24.15 - $42.89 $23.4 Million - $41.6 Million
968,959 Added 44.91%
3,126,502 $75.5 Million
Q4 2024

Feb 12, 2025
BUY
$38.28 - $78.03 $1.57 Million - $3.21 Million
41,105 Added 1.94%
2,157,543 $86.8 Million
Q3 2024

Dec 26, 2024
SELL
$49.84 - $70.47 $6.74 Million - $9.53 Million
-135,233 Reduced 6.01%
2,116,438 $134 Million
Q3 2024

Nov 08, 2024
SELL
$49.84 - $70.47 $6.74 Million - $9.53 Million
-135,233 Reduced 6.01%
2,116,438 $134 Million
Q2 2024

Dec 26, 2024
BUY
$47.39 - $80.2 $6.41 Million - $10.8 Million
135,233 Added 6.39%
2,251,671 $119 Million
Q2 2024

Aug 12, 2024
BUY
$47.39 - $80.2 $57.4 Million - $97.2 Million
1,211,513 Added 116.47%
2,251,671 $119 Million
Q1 2024

Dec 26, 2024
SELL
$17.4 - $94.5 $18.7 Million - $102 Million
-1,076,280 Reduced 50.85%
1,040,158 $85.3 Million
Q1 2024

May 10, 2024
BUY
$17.4 - $94.5 $8.22 Million - $44.7 Million
472,566 Added 83.26%
1,040,158 $85.3 Million
Q4 2023

Dec 26, 2024
SELL
$9.24 - $19.64 $14.3 Million - $30.4 Million
-1,548,846 Reduced 73.18%
567,592 $10.6 Million
Q4 2023

Feb 12, 2024
BUY
$9.24 - $19.64 $96,317 - $204,727
10,424 Added 1.87%
567,592 $10.6 Million
Q3 2023

Nov 14, 2023
BUY
$10.92 - $16.0 $116,134 - $170,160
10,635 Added 1.95%
557,168 $6.17 Million
Q2 2023

Aug 11, 2023
BUY
$14.84 - $24.79 $8.07 Million - $13.5 Million
543,895 Added 20617.7%
546,533 $8.86 Million
Q1 2023

May 11, 2023
BUY
$8.08 - $17.33 $17,291 - $37,086
2,140 Added 429.72%
2,638 $43,000
Q4 2022

Feb 13, 2023
SELL
$2.72 - $9.4 $77,547 - $267,994
-28,510 Reduced 98.28%
498 $4,000
Q3 2022

Nov 14, 2022
SELL
$2.55 - $3.89 $43,546 - $66,429
-17,077 Reduced 37.06%
29,008 $80,000
Q2 2022

Aug 11, 2022
BUY
$2.11 - $3.15 $27,835 - $41,554
13,192 Added 40.11%
46,085 $134,000
Q1 2022

May 11, 2022
BUY
$3.0 - $4.88 $16,818 - $27,357
5,606 Added 20.54%
32,893 $99,000
Q4 2021

Feb 10, 2022
BUY
$4.6 - $6.72 $5,299 - $7,741
1,152 Added 4.41%
27,287 $124,000
Q3 2021

Nov 12, 2021
BUY
$5.58 - $7.04 $145,833 - $183,990
26,135 New
26,135 $164,000

Others Institutions Holding VKTX

# of Institutions
433
Shares Held
66.6M
Call Options Held
7.21M
Put Options Held
3.87M
View Full List

About Viking Therapeutics, Inc.

VKTX Quotes by TradingView
  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email